Proceedings · Session S-972 · filed November 17, 2026

Translational ScienceSession paper

Cretostimogene Cuts Bladder Cancer Recurrence Risk 68% in Phase 3

Cretostimogene cut bladder cancer recurrence risk 68% (HR 0.32) in Phase 3, while FDA rejected Summit's ivonescimab BLA and Aclaris's Phase 2 antibody missed endpoints.

By Sophie Lindqvist4 min read847 words

Summary

  • Cretostimogene reduced bladder cancer recurrence risk 68% vs control (HR 0.32; p<0.0001) in the 367-patient Phase 3 PIVOT-006 trial; BLA planned Q2 2027.
  • Lexeo's LX2020 high-dose cohorts showed 80% mean reduction in non-sustained ventricular tachycardia; 10 participants dosed, 9 at ≥12 months follow-up.
  • FDA issued a complete response letter for Summit's ivonescimab BLA; shares fell 16.5%.
  • Aclaris's Phase 2 ADMIRATION trial of bosakitug missed primary and secondary endpoints in atopic dermatitis.
  • Research and Markets projects the bladder cancer drugs market to grow from $6.89B (2026) to $11.84B (2032), 9.41% CAGR.
Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection
FigureBiotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection — DarkoStojanovic / pixabay

CG Oncology's Phase 3 PIVOT-006 trial of adjuvant intravesical cretostimogene met its primary endpoint, cutting recurrence risk by 68% against control in non-muscle invasive bladder cancer, with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001). The result anchors a Monday, November 16, 2026 news cycle that ran in both directions for drug developers — two trial wins, one Phase 2 miss and one FDA rejection — against a falling broader market.

The S&P 500 dropped 1.92% to 7,416.59 and the Nasdaq Composite fell 2.49% to 24,509.76, according to CNBC's closing report. Bladder cancer, one of the day's focal areas, sits inside a market that Research and Markets projects will grow from $6.89 billion in 2026 to $11.84 billion by 2032 — a 9.41% compound annual growth rate and a third-party projection, not a measured figure.

What did PIVOT-006 actually show?

The trial enrolled 367 patients across roughly 90 sites in the United States and Canada. All had intermediate-risk and high-grade Ta non-muscle invasive bladder cancer measuring 3 cm or less, following complete tumor resection. The 68% recurrence-risk reduction and hazard ratio of 0.32 constitute the topline primary-endpoint result; full data are scheduled for presentation at the Society of Urologic Oncology Annual Meeting on December 2, 2026.

CG Oncology (NASDAQ: CGON) plans to submit a biologics license application on the PIVOT-006 data in the second quarter of 2027 — a company timeline, not a regulatory commitment. Cretostimogene remains an investigational candidate.

What did Lexeo's gene therapy interim data deliver?

Lexeo Therapeutics (NASDAQ: LXEO) reported positive interim Phase I/II data for LX2020, its investigational gene therapy for PKP2 arrhythmogenic cardiomyopathy, an inherited heart disease. Participants in the high-dose cohorts achieved an 80% mean reduction in non-sustained ventricular tachycardia and a 44% mean reduction in premature ventricular contractions at latest assessment.

The numbers rest on a small base: ten participants dosed in total, with nine reaching at least 12 months of follow-up as of the October 15, 2026 data cutoff. Interim results may change as data mature.

Lexeo also disclosed that the FDA is open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020 — a pathway signal rather than an approval decision. The company released the update alongside its third quarter 2026 financial results.

Why did the FDA reject ivonescimab?

Summit Therapeutics (NASDAQ: SMMT) said the FDA issued a complete response letter for its biologics license application for ivonescimab combined with platinum-based chemotherapy in previously treated EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer. The agency concluded that substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival improvement, according to the company.

The application rested on the global Phase III HARMONi trial. Per the company's SEC filings, ivonescimab plus chemotherapy delivered a statistically significant progression-free survival improvement, hazard ratio 0.52, while overall survival showed only a positive trend that missed statistical significance. Summit shares fell 16.5% after the decision, the Associated Press reported.

The rejection draws a hard line for portfolio planning: a significant PFS benefit alone did not carry this application through review in this indication.

How badly did bosakitug miss?

Aclaris Therapeutics (NASDAQ: ACRS) reported that its Phase 2 ADMIRATION trial of bosakitug (ATI-045), an investigational anti-TSLP monoclonal antibody, failed to achieve its primary or secondary endpoints in moderate-to-severe atopic dermatitis. The primary endpoint measured percent change from baseline in Eczema Area and Severity Index score at week 24.

The pharmacodynamic data offered a partial explanation of the miss: Aclaris said results showed robust TSLP target engagement and downregulation of Th1-, Th2- and Th17-related immune-activation biomarkers. The drug was generally well tolerated. Strong target engagement without clinical efficacy raises questions about the mechanism's relevance to the endpoint that only further data can answer.

Aclaris also disclosed that it initiated the Phase 2b ALPHA trial of modzatinib in patients with moderate-to-severe lichen planus, shifting resources toward a separate dermatology program.

What should R&D managers take from the split?

Three of the four developments carry direct portfolio implications. CG Oncology's 367-patient Phase 3 result with a hazard ratio of 0.32 moves cretostimogene toward a Q2 2027 BLA filing, pending the December 2 topline presentation. Lexeo's ten-participant interim set, paired with an FDA endpoint signal, de-risks — modestly — the accelerated-approval route for LX2020. Summit's complete response letter demonstrates that a PFS hazard ratio of 0.52 without overall survival significance can sink an application, while Aclaris's bosakitug miss shows biomarker engagement does not guarantee clinical endpoints.

All product candidates discussed remain investigational, unapproved for the uses described, and their topline and interim results are preliminary and may not predict final outcomes. Topline PIVOT-006 data on December 2, 2026 is the next concrete checkpoint.

via prnewswire.com (Source)

Filed under

  • clinical-trials
  • drug-development
  • fda-regulation
  • oncology
  • biotechnology
Share this article:

More from Sophie Lindqvist

Sophie Lindqvist

Show full bio

Correspondent covering money, funding and market shifts around research and development at Hypothesis Wire.

242 articles

References

  1. Cancer Vaccine Beats Survival Endpoint, But Patent Clock Looms
  2. Federal Cancer Research Budgets Rose After a Year of Uncertainty
  3. AstraZeneca bets on oncology plus diversification for 2026
  4. Recursion Targets H2 2027 Pivotal Trial After REC-4881 Cuts FAP Polyps 47%
  5. FDA Clears Two AstraZeneca Biologics in Four Days

« Previous articleNext article »